Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
Ben W R BalzerChristine LooEva A WegnerChrista Ellen NathSamiuela LeeChantelle SmithCraig R LewisToby N TrahairAntoinette C AnazodoPublished in: Pediatric hematology and oncology (2018)
Anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib and alectinib have been shown to have significant activity in ALK-rearranged non-small cell lung cancers (NSCLC). There are no data for alectinib's safety or efficacy in younger patients, though it is superior to crizotinib in adult trials. We present a 14-year old girl diagnosed with stage IV-B ALK-positive adenocarcinoma of the lung after presenting with cough and fever. She was commenced on alectinib at adult dose and has had sustained complete metabolic remission for 9 months. She is the youngest patient with lung adenocarcinoma to be treated with alectinib.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- newly diagnosed
- squamous cell carcinoma
- case report
- childhood cancer
- young adults
- chronic kidney disease
- small cell lung cancer
- peritoneal dialysis
- single cell
- prognostic factors
- mental health
- radiation therapy
- machine learning
- diffuse large b cell lymphoma
- systemic lupus erythematosus
- bone marrow
- ulcerative colitis
- disease activity
- brain metastases